New Framework Proposes Better Stroke Care via BP Timing

Researchers from The People’s Hospital Medical Group of Xiangzhou in Zhuhai, China, have proposed a new theoretical framework to guide blood pressure management in acute intracerebral haemorrhage. The study, published in Frontiers in Neurology, introduces a Time–Trajectory–Phenotype model that argues clinical outcomes depend not just on the target blood pressure, but on how quickly it is reached, how steadily it is maintained, and the individual patient’s physiological tolerance. This hypothesis-driven article synthesizes existing clinical evidence and biological mechanisms to suggest that early, stable control of blood pressure may offer greater net benefit than delayed or fluctuating management during the critical first three hours after a stroke.

Spontaneous intracerebral haemorrhage remains a devastating subtype of stroke, characterized by high mortality and long-term disability. Following the initial rupture of a blood vessel, ongoing bleeding can enlarge the haematoma while secondary tissue injury begins to evolve. Blood pressure is a readily accessible target because it can be closely monitored and rapidly modified. The central challenge for clinicians is to reduce arterial pressure, which may sustain ongoing bleeding, while simultaneously preserving adequate perfusion to the brain and other vital organs. The authors note that a single blood pressure measurement can mask very different haemodynamic trajectories, such as rapid stabilization versus prolonged hypertension or hypotensive episodes.

The proposed framework distinguishes three dimensions: Time, Trajectory, and Phenotype. Time encompasses the delay from symptom onset to treatment initiation and the interval from drug administration to actual target achievement. Trajectory accounts for the magnitude and rate of the initial blood pressure reduction, subsequent variability, and the duration of deviations outside the target range. Phenotype denotes baseline patient characteristics that influence the risk of haematoma expansion and the tolerance of blood pressure reduction. The authors hypothesize that achieving an appropriate blood pressure range early, followed by sustained maintenance, offers greater clinical benefit than delayed or unstable control, provided that further haematoma expansion remains preventable and the patient can tolerate the reduction.

The clinical rationale for this framework is supported by landmark randomized trials, including INTERACT2 and ATACH-II. INTERACT2 enrolled 2,839 patients and compared intensive blood pressure lowering with standard treatment. While the primary binary endpoint of death or major disability was not significantly reduced, a prespecified ordinal analysis showed a modest but statistically significant favorable shift in functional scores. Conversely, ATACH-II, which enrolled 1,000 patients, found that a more intensive systolic target did not improve functional outcomes and was associated with a significantly higher incidence of renal adverse events. These findings highlight the need to evaluate more than a single target value, as neither trial prospectively randomized patients to compare early versus late target achievement or smooth versus fluctuating trajectories.

Further evidence from the INTERACT4 trial investigated prehospital, ambulance-delivered blood pressure reduction within two hours of symptom onset. While the overall functional outcome for the cohort was neutral, subgroup analyses revealed contrasting effects: patients diagnosed with haemorrhagic stroke had better functional outcomes, whereas those with cerebral ischaemia experienced worse outcomes. This underscores the importance of diagnostic certainty and rapid neuroimaging differentiation. Additionally, an individual-participant-data meta-analysis of 16 trials involving 6,221 patients found that blood pressure-lowering interventions reduced haematoma expansion without an overall improvement in functional outcomes, highlighting a gap between imaging results and clinical recovery.

The authors identify the first three hours as a clinically motivated focus for research. A 2025 pooled analysis of four INTERACT trials suggested that the effects of intensive treatment on function and haematoma growth diminish with later randomisation, with point estimates crossing the null effect line at approximately three hours. This pattern is consistent with a narrowing opportunity to prevent additional injury as active bleeding subsides. However, the authors clarify that this three-hour mark is a statistical estimate rather than a measurement of haemostasis, and it serves as a research reference within a continuous, time-dependent process. Patients presenting later still require treatment according to clinical indications, but the therapeutic opportunity is greatest during this initial window.

The trajectory component of the framework emphasizes that mean blood pressure alone can obscure clinically relevant excursions. Post-hoc analyses of INTERACT2 and ATACH-II consistently associate greater systolic blood pressure variability with poorer outcomes. The authors propose time-in-target range as a candidate measure of sustained control, which distinguishes sustained control from a single in-range reading. They also note that the magnitude of the initial blood pressure fall adds prognostic information; pooled data showed a J-shaped association between reduction magnitude and outcome, and an emergency-department study associated overshooting below 120 mmHg with worse discharge outcomes. These findings support recording the starting value, pressure nadir, and duration below the intended range to better understand the quality of blood pressure delivery.

The phenotype dimension addresses two distinct clinical dimensions: expansion risk and treatment tolerance. To characterize expansion risk, baseline haematoma volume, intraventricular extension, and imaging markers such as the blend and black-hole signs on non-contrast CT are relevant. The authors distinguish between prognostic enrichment, where higher baseline risk yields a larger absolute benefit, and predictive biomarkers that modify relative efficacy. For instance, a prospective analysis found no detectable interaction between the CT angiography spot sign and rapid target achievement regarding haematoma expansion. Treatment tolerance depends on cerebral perfusion dynamics and systemic physiological reserve. Aggressive arterial blood pressure reduction in the setting of severely elevated intracranial pressure can compromise the pressure gradient essential for brain perfusion, necessitating a careful balance between reducing bleeding and maintaining perfusion.

Biological mechanisms provide a rationale for why treatment timing and blood pressure stability matter beyond the achieved pressure. During active bleeding, haemodynamic load may influence the mechanical stability of local haemostasis. Experimental fibrin studies link clot strength to its microarchitecture and cross-linking density, suggesting that recurrent pressure excursions could destabilize a forming haemostatic plug more than a stable exposure with a comparable mean pressure. Furthermore, mechanical stress can activate intracellular signalling pathways that lead to blood-brain barrier disruption. In a rat model, pharmacological blockade of TRPV4 reduced stress-fibre-associated barrier disruption, supporting a channel-cytoskeleton-barrier mechanism in experimental intracerebral haemorrhage. These biological processes evolve over hours to days, providing distinct mechanisms through which treatment timing and blood pressure stability could influence outcome.

The authors propose that future prospective studies should test these predictions by randomizing delivery protocols with the same blood pressure target but different timing and stability. Such trials should measure time-in-target range, blood pressure variability, and above- and below-range exposure to confirm which aspects of the trajectory actually differ between strategies. The framework also suggests that baseline expansion risk and haemodynamic vulnerability should explain differences in net clinical benefit. To validate these hypotheses, studies must distinguish a larger absolute benefit associated with higher baseline risk from a treatment-by-phenotype interaction. Functional outcome should remain central, assessed using a prespecified modified Rankin Scale endpoint alongside mortality, neurological deterioration, and renal adverse events.

Immediate clinical application of this framework involves improving the delivery and measurement of established care. Upon CT confirmation of intracerebral haemorrhage, clinicians should evaluate presenting blood pressure, neurological severity, and anticoagulant exposure simultaneously. For mild-to-moderate cases, guidelines support considering a target of 140 mmHg and subsequent maintenance at 130–150 mmHg. Achieving a predictable haemodynamic trajectory requires suitable pharmacological agents, such as nicardipine or clevidipine infusions, which allow minute-to-minute dose adjustment. Continuous or high-frequency blood pressure measurements should be coupled with neurological assessments and monitoring of systemic perfusion, including creatinine and urine output, to evaluate renal safety. Blood pressure control is one component of coordinated, multidisciplinary care that includes anticoagulant reversal and surgical evaluation when indicated.

The study concludes that hyperacute blood pressure management is a dynamic physiological exposure whose clinical effects depend on when control is achieved, how pressure evolves, and the patient’s capacity to tolerate the intervention. The Time–Trajectory–Phenotype framework brings these dimensions into a common, testable hypothesis. While the first three hours provide a clinically motivated focus, treatment time should be analyzed continuously across the acute period. Prospective trials are needed to determine whether faster delivery and more stable control improve function and safety, and whether baseline phenotypes identify different treatment effects. Phase-specific experiments on haemostasis, barrier integrity, and fluid transport can further establish which mechanisms connect blood pressure delivery to subsequent injury and recovery.

Subject of Research: Blood pressure management in acute intracerebral haemorrhage: a Time–Trajectory–Phenotype framework

Article Title: Blood pressure management in acute intracerebral haemorrhage: a Time–Trajectory–Phenotype framework

Article References: Xia, X. P., Zhang, Y., & Zhao, L. (2026). Blood pressure management in acute intracerebral haemorrhage: a Time–Trajectory–Phenotype framework. Frontiers in Neurology, 17, Article 1900479. https://doi.org/10.3389/fneur.2026.1900479

Image Credits: AI Generated

DOI: 10.3389/fneur.2026.1900479

Keywords: Blood, pressure, management, acute, intracerebral, haemorrhage, Time, Trajectory, Phenotype, framework, scientific research